Left ventricular hypertrophy influences cardiac prognosis in patients undergoing dobutamine cardiac stress testing

Charaslak Charoenpanichkit1, Timothy M Morgan, Craig A Hamilton

  • 1Departments of Internal Medicine Cardiology Section, Public Health Sciences, Biomedical Engineering, and Radiology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1045, USA.

Insights

Left ventricular hypertrophy (LVH) predicts myocardial infarction (MI) and cardiac death in patients undergoing dobutamine stress tests. Reporting LVH is crucial, especially for patients without inducible ischemia, to refine cardiac risk assessment.

Area of Science:

  • Cardiology
  • Diagnostic Imaging
  • Cardiac Physiology

Background:

  • Chest pain is a common symptom requiring accurate diagnosis.
  • Left ventricular hypertrophy (LVH) is a structural heart change that may impact cardiac prognosis.
  • Dobutamine stress testing is used to evaluate patients with suspected or known coronary artery disease.

Purpose of the Study:

  • To assess the predictive value of dobutamine stress test findings for myocardial infarction (MI) and cardiac death.
  • To determine if left ventricular hypertrophy (LVH) independently predicts adverse cardiac events.
  • To evaluate the utility of dobutamine stress testing in patients with chest pain and LVH.

Main Methods:

  • 353 participants with chest pain underwent dobutamine cardiovascular magnetic resonance (CMR) stress testing.
  • Participants were followed for a mean of 6 years to track MI or cardiac death.
  • Left ventricular (LV) mass was measured, with LVH defined by sex-specific mass index criteria.

Main Results:

  • LVH was present in 17-18% of participants.
  • 20% of participants experienced MI or cardiac death during follow-up.
  • LVH was an independent predictor of MI and cardiac death (HR=1.99, P=0.02) in multivariable analysis, even in the presence of ischemia.

Conclusions:

  • Left ventricular hypertrophy (LVH) is a significant predictor of future MI and cardiac death.
  • LVH should be reported in dobutamine stress test results, particularly for patients without inducible ischemia.
  • Identifying LVH can help refine risk stratification and patient management.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...